Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;22(10):589-590.
doi: 10.1038/s41577-022-00764-7.

Respiratory syncytial virus after the SARS-CoV-2 pandemic - what next?

Lucy G Mosscrop  1 , Thomas C Williams  2 , John S Tregoning  3
Affiliations

Respiratory syncytial virus after the SARS-CoV-2 pandemic - what next?

Lucy G Mosscrop et al. Nat Rev Immunol. 2022 Oct.

Abstract

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection. It is a large contributor to infant hospitalization and also has a substantial burden in older adults ( ≥ 65 years). The non-pharmaceutical interventions that were introduced to limit the spread of SARS-CoV-2 have had a marked effect on the transmission of RSV, particularly its seasonality. Here, we consider the implications of these changes to RSV transmission for future prevention strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Eden J-S, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat. Commun. 2022;13:2884. doi: 10.1038/s41467-022-30485-3. - DOI - PMC - PubMed
    1. Li Y, et al. Understanding the potential drivers for respiratory syncytial virus rebound during the coronavirus disease 2019 pandemic. J. Infect. Dis. 2022;225:957–964. doi: 10.1093/infdis/jiab606. - DOI - PMC - PubMed
    1. Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 2021;19:741–742. doi: 10.1038/s41579-021-00642-4. - DOI - PMC - PubMed
    1. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531. - DOI - PubMed
    1. Hammitt LL, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 2022;386:837–846. doi: 10.1056/NEJMoa2110275. - DOI - PubMed